readthroughSign in
Nov 10, 2026FinancingUpdated

Prime Medicine launches $125 million stock offering, details Wilson disease and AATD progress

The gene-editing company priced a public offering as it reported dosing its first Wilson disease patient and cleared INDs for two liver programs.

Prime Medicine, Inc. filed a preliminary prospectus supplement on November 10, 2026 for a public offering of $125,000,000 of common stock, with an underwriters' option for up to an additional $18,750,000 of shares. The stock is listed on Nasdaq under the symbol PRME, and closed at $4.30 per share on November 9, 2026.1 The company said it intends to use the net proceeds, together with existing cash, primarily to advance its Wilson disease and AATD programs and other research and development, with the remainder for working capital and general corporate purposes.1

On the pipeline, Prime said in October 2026 that the first patient had been dosed in its global Phase 1/2 clinical trial of PM577a, with initial clinical data expected in 2027.1 Also in October 2026, the FDA granted Rare Pediatric Disease designation to PM577.1 In September 2026, the FDA cleared the company's IND application for PM647 in AATD, enabling a global Phase 1/2 study to begin in the United States.1 Initial clinical data from that trial are also expected in 2027.1

On chronic granulomatous disease, Prime said it continues regulatory dialogue with the FDA toward a BLA submission for PM359, planned for the first half of 2027, after the FDA granted Regenerative Medicine Advanced Therapy designation for PM359 in June 2026.1

On financials, the company estimated cash, cash equivalents, and short-term investments of approximately $61.2 million as of September 30, 2026, excluding restricted cash of approximately $13.7 million.1 It said as of June 30, 2026, it had net tangible book value of approximately $39.8 million, or $0.22 per share, based on 180,737,548 shares outstanding.1 Complete results for the September quarter will appear in its Form 10-Q.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.